NDA 212782 · Shilpa
Bortezomib
Bortezomib · Intravenous, Subcutaneous · Proteasome Inhibitor
Last checked: Nov 20, 2026Latest source record: Aug 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Aug 26, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,027
156 Phase 3, 82 recruiting
FAERS reports
33,996
32,180 serious, 6,006 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 5, 2025.
BORUZU is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma BORUZU is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma BORUZU is indicated for the treatment of adult patients with mantle cell lymphoma.
Mechanism: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BORTEZOMIB · BORTEZOMIB 3.5MG/1.4ML (2.5MG/ML) · SOLUTION, INTRAVENOUS, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bortezomib" as an intervention, any sponsor and status, largest first.
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsPivotal-lookingStatus unknown
University of LeedsAcademic, hospital or other
NCT01554852 · 4,420 participants · Start May 2010 · Primary completion Dec 2021
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen; Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen and 7 more · For: Multiple Myeloma
Sites: United Kingdom, United Kingdom
- Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)Pivotal-lookingStatus unknown
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyAcademic, hospital or other
NCT03390387 · 4,000 participants (planned) · Start Nov 2015 · Primary completion Nov 2020
Drug: Dexamethasone continuous; Dexamethasone intermittent and 8 more · For: Childhood Acute Lymphoblastic Leukemia
Sites: Yerevan, Armenia; Homyel, Belarus; Minsk, Belarus · 58 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01371981 · 1,645 participants · Start Jul 6, 2011 · Primary completion Mar 31, 2019
Drug: Asparaginase; Bortezomib and 5 more · For: Acute Myeloid Leukemia; Leukemia Cutis; Myeloid Neoplasm and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 220 sites in all
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple MyelomaPivotal-lookingCompleted
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT01208766 · 1,503 participants · Start Jan 2011 · Primary completion Dec 2020
Drug: Bortezomib, Melphalan, Prednisone (VMP); 1 or 2 cycle(s) HDM (High Dose Melphalan) and 1 more · For: Multiple Myeloma
Sites: Brisbane, Australia; Canberra, Australia; Melbourne, Australia · 208 sites in all
Wei ZhaoAcademic, hospital or other
NCT03844360 · 1,500 participants (planned) · Start Jan 31, 2016 · Primary completion Dec 31, 2025
Drug: Bortezomib; Eltrombopag and 5 more · For: Hematological Neoplasms
Sites: Xuzhou, China; Tanjin, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- plasma cell myeloma5,249
- off label use3,253
- drug ineffective2,307
- neuropathy peripheral1,904
- thrombocytopenia1,807
- death1,591
- pneumonia1,575
- neutropenia1,428
- diarrhoea1,414
- fatigue1,162
- anaemia1,136
- disease progression1,072
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 25 |
| 2006 | 17 |
| 2007 | 37 |
| 2008 | 78 |
| 2009 | 161 |
| 2010 | 248 |
| 2011 | 313 |
| 2012 | 409 |
| 2013 | 556 |
| 2014 | 800 |
| 2015 | 1,311 |
| 2016 | 1,077 |
| 2017 | 1,232 |
| 2018 | 1,699 |
| 2019 | 2,521 |
| 2020 | 3,037 |
| 2021 | 3,110 |
| 2022 | 3,923 |
| 2023 | 3,918 |
| 2024 | 3,760 |
| 2025 | 3,243 |
| 2026 | 2,506 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bortezomib* (Bortezomib)
2024 spending
$3.1M
Beneficiaries
719
4,286 claims
Per beneficiary
$4,318
$261.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,261,525 |
| 2021 | $3,209,334 |
| 2022 | $4,278,056 |
| 2023 | $3,999,340 |
| 2024 | $3,104,837 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Leleu X, Hulin C, Lambert J, et al. · Nat Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
Teachey DT, Devidas M, Wood BL, et al. · J Clin Oncol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Hungria V, Robak P, Hus M, et al. · Lancet Oncol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, et al. · Lancet Oncol 2016 · Clinical Trial, Phase III, Comparative Study
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
Sonneveld P, Chanan-Khan A, Weisel K, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Shilpa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.